Hi ,

The European Academy of Dermatology and Venereology (EADV) Congress just wrapped up in Paris.

And this year, vitiligo was in the air — like a fine French perfume, subtle but impossible to ignore.

Vitiligo has never gotten this much attention from Big Pharma. Ever.

New systemic drugs are in Phase II and III — human trials are underway. If all goes well, we might see better, lasting treatments in 5–7 years.

A long wait for adults who’ve lived with vitiligo for decades. But for kids? This could change everything.

Even more surprising: the usual cutthroat competition among Big Pharma is giving way to quiet collaboration. Behind the scenes, companies are actually sharing knowledge — all to get better drugs to patients, faster.

🔬 NOT JUST SKIN — NOT ANYMORE

The narrative is finally shifting. Vitiligo is no longer dismissed as “just cosmetic.” Clinicians, pharma teams, researchers — they’re all catching up to what patients already knew:

Vitiligo is a chronic autoimmune disease, now with five phenotypes identified, that often demands serious, long-term management.

📌 VITILIGO PIPELINE AND MARKET   

Our latest Vitiligo Drug Pipeline Analysis and Market Insights is now live.  This updated edition includes:

• New Phase II & III drugs — both systemic and topical 
• Updated targets: JAK, TYK2, IL-15, IFN-γ, PD-1, and more 
• M&A moves, biotech newcomers, and regional activity, including key players from India and China.  

If you want to know what’s coming next in vitiligo treatment — and who’s driving it — this is the one to read.

🗂️ MORE NEWS? YOU BET

Vitiligo research is picking up speed — fast.

We’ve revamped our website to keep up. Now find daily insights, trusted answers, and unexpected gems in one place, like:

• Vitiligo and pregnancy — what’s safe, what’s not
• The real price tag of treating vitiligo, with medicare & insurance updates
• ZIP code and vitiligo? Yep, finally connected!

And for Podcast lovers, we've just published our 45th episode Deep Dive In Vitiligo. It's available on all digital platforms: Apple Podcasts, Spotify, Podbean, and elsewhere. 

Until next time,




Yan Valle
Prof., CEO VR Foundation